Does Semaglutide Cause Liver Damage? Key Things to Know

Millions of people globally are worried about liver health when starting new medications. Concerns like “does semaglutide cause liver damage” is understandable given how important the role of liver in our body is.

In this article, we will have a deep dive on what research is saying about semaglutide, what it is, how it works, and how it helps liver health instead of causing harm.

Key Points

• Research suggests semaglutide does not typically cause liver damage

• It may improve liver health in conditions like nonalcoholic fatty liver disease (NAFLD)

• Rare cases of liver injury have been reported, but they are not common

• Always consult a healthcare provider if you have liver concerns

Did You Know?

A study found that 62.9% and 36.8% of patients taking semaglutide have resolution of steatohepatitis and reduction of liver fibrosis, respectively?

What is Semaglutide and How Does It Work?

Semaglutide is a medicine (GLP-1 receptor agonist) that acts like a hormone in your body. It helps control blood sugar and support weight loss. It works similarly to the natural hormone in managing insulin and slowing down digestion.

Semaglutide is one of the most talked-about medications in recent years. It earned the spotlight for its dual benefits in the management of type 2 diabetes and supporting weight loss.

The Food and Drug Administration (FDA) has approved it under different brand names—Ozempic, Rybelsus and Wegovy. Both formulations contain the same active ingredient. However, each of these drugs are prescribed at different doses to achieve a specific health goal.

The drug works by targeting a specific receptor—GLP-1 receptor. In particular, it targets this specific receptor found in areas that control blood sugar and appetite. The documented benefits of semaglutide include:

• Promotes insulin release when your blood sugar becomes elevated

• Reduction of glucagon production to prevent the liver from releasing stored glucose

• Slows down the emptying of your stomach to help you feel full longer after every meal

• Acts on the brain receptors to control appetite and ease food cravings

This is a comprehensive approach that makes semaglutide efficient for people with type 2 who are struggling to control their blood sugar. It is also effective for people who are dealing with obesity or weight-related health conditions for a long time.

The medication is administered in a once-weekly injection dosing. Hence, it is convenient for long-term management.

Is There Evidence That Semaglutide Causes Liver Damage?

If you are worried about potential liver effects when starting a new medication then this concern is understandable. Your liver processes everything you consume, so it’s natural to wonder how semaglutide may affect your liver.

Fortunately, extensive research is done and clinical experience has not shown semaglutide to cause liver damage in the majority of users. In fact, studies suggest that the medication actually offers benefits for liver health instead of harming it.

What Do Clinical Studies Say?

Clinical trials show that semaglutide poses no significant threat to the liver in most patients. In fact, the common adverse events reported were gastrointestinal effects.

Research found out that patients taking semaglutide had reduction of ALT (alanine transaminase) levels by 6-21% from baseline. In the same study, ALT normalization was found in 25-46% of subjects compared to placebo.

The clear absence of a relationship between semaglutide and liver damage is evidence that the drug doesn’t have any substantial liver effects. It also has a good overall safety profile, which led to a conclusion that there is minimal to no threat to the liver.

Are There Any Reported Cases of Liver Damage?

Yes, but rare. The literature has reported isolated cases where drug-induced liver injury occurred.

The overall safety profile is excellent for semaglutide. The rare reports often involve individuals with multiple risk factors or underlying conditions. Reports find that the following group of people have increased risk for drug-induced liver injury as a result of semaglutide intake:

• Pre-existing liver conditions even before taking semaglutide

• Taking multiple medications that may affect liver function

• Underlying medical conditions contributing to liver problems (as in the case of the patient with obesity and sleep-related eating disorder)

• Experienced rapid weight loss, which sometimes affect the liver enzymes

In another study, semaglutide at 0.4/0.5 mg weekly significantly improves liver-related biomarkers, metabolic parameters, and weight. But is associated with a higher rate of gastrointestinal side effects and treatment discontinuation. However, the most common effect was diarrhea at 66% followed by vomiting at 54%.

It is good to emphasize that the isolated reports on drug-induced liver injury don’t entirely establish a direct causal relationship between these entities. Many factors influence liver health. Often, it is hard to pinpoint the exact single cause when liver problems develop.

How Common Is Liver Damage with Semaglutide?

Liver toxicity is not listed as a recognized side effect on semaglutide’s FDA-approved labeling. It reflects the drug’s strong safety record regarding liver health.

Comparing semaglutide to other diabetes and weight-loss medications, its liver safety profile stands out. In the STEP clinical trial that led to the FDA approval of semaglutide with liver monitoring, it is found that:

• Approximately 6,000 patients were monitored

• Baseline liver function test was done and compared throughout the trial

• Semaglutide has not been associated with significant liver toxicity

• Some trials (like STEP 1 and other GLP-1 trials) reported improvements in liver enzymes, likely related to weight loss and reduced hepatic steatosis

Even after the drug has been marketed and distributed, monitoring of adverse events or other side effects did not reveal any direct liver injury associated with semaglutide intake. The ongoing monitoring system can quickly determine whether liver problems occur at a higher than expected levels.

What does this mean for you? It means that regular liver monitoring may not be necessary for most patients taking semaglutide. However, it is important to note that your doctor may still check your liver enzymes from time to time as part of a complete diabetes or weight management care.

Can Semaglutide Improve Liver Health?

Yes, research has shown that semaglutide has an indirect effect on liver health. The specific benefits will be discussed in the subsequent sections.

Semaglutide's Role in Treating Non-Alcoholic Fatty Liver Disease (NAFLD)

In a study, researchers concluded that taking semaglutide for 24 weeks can help improve liver health in people with NAFLD or NASH.

NAFLD affects approximately 25% of the population in the United States. Thus, it is one of the most common conditions affecting the liver. It occurs when fat builds up in the liver cells, making them swell. It is often linked to obesity, diabetes, and metabolic syndrome.

Semaglutide is formulated to address these issues. What can semaglutide do?

• Reduces fat content in the liver by 31% of people (even those with HIV and metabolic dysfunction-associated steatotic liver disease [MASLD])

• Improves liver scarring or fibrosis

• Reduces the inflammatory markers linked to liver disease

• Supports overall metabolic health that benefits liver function

Many studies have used advanced MRI imaging to measure the fat content before and after the semaglutide therapy. It is an objective way of finding out whether the medication really helps the liver recover from fat accumulation and fibrosis.

Also, the weight loss associated with semaglutide helps a lot in improving NAFLD. A modest weight loss of about 5-10% can result in significant improvements in fatty liver and inflammation markers.

Semaglutide helps people who are struggling to lose weight from diet and exercise. Its support in liver health is an indirect benefit you can get even when you primarily want to control obesity.

People with NAFLD may also notice significant improvement in related conditions like elevated cholesterol, high blood pressure, and insulin resistance, which are factors that contribute to overall liver health.

Improvements in Liver Enzymes and Inflammation

In a study, semaglutide treatment in patients with liver-related conditions demonstrated significant benefits, including reductions in liver enzymes (ALT and AST), liver fat content, and liver stiffness. In addition, it improved metabolic parameters such as glycated hemoglobin and lipid profiles.

The improvement in liver enzyme levels holds true even with people who didn’t have elevated liver enzymes at the beginning of therapy. The anti-inflammatory properties of semaglutide offer benefits that go beyond liver benefits. Semaglutide can:

• Lower down C-reactive protein (CRP), which is an inflammatory marker

• Affect inflammatory cytokines

• Reduce oxidative stress markers

• Improve overall metabolic inflammation

Your doctor will monitor your liver enzymes periodically as part of the routine care, particularly if you have diabetes and obesity. The reduction in inflammatory markers help slow down the progression from simple fatty liver disease to more serious conditions like non-alcoholic steatohepatitis (NASH), which can improve potential scarring and liver inflammation.

Weight Loss and Its Impact on Liver Health

The substantial weight loss achieved when starting semaglutide indirectly benefits the liver by reducing the metabolic burden from this organ. Excess weight, especially abdominal fat, can contribute to the buildup of fat in the liver and inflammation.

• Research shows that the main therapy for people with NASH is losing weight, which can be achieved through semaglutide once-weekly dosing. If you lower your body mass index (BMI) by 5%, it can reduce liver fat by 25%.

• Losing weight by > 5-10% from baseline leads to improvement of liver steatosis

Just imagine if you have sustained weight loss, what benefits would this offer to your overall liver health?

Clinical trials have shown that semaglutide can help people lose 10-15% of their body weight when combined with lifestyle changes. For diabetes management, it can significantly reduce A1C levels while also providing cardiovascular benefits. The dual action on both metabolic and weight-related factors has made it a valuable tool in treating conditions that often occur together.

Who Should Be Cautious About Using Semaglutide?

There are certain groups of people who should discuss liver health considerations with their healthcare providers before starting semaglutide. The medication has an excellent safety profile and is generally well-tolerated. However, certain precautions must be exercised and personalized medical assessment is always important.

If you have any of the following conditions, it would be best to talk to your doctor:

• Individuals with pre-existing liver disease such as hepatitis or cirrhosis

• People taking medications known to affect liver function

• Those with a history of liver problems from other medications

• Individuals with excessive alcohol consumption that could affect liver health

• People with multiple risk factors for liver disease

The process of having the medication FDA-approved is extensive and requires comprehensive safety testing. However, individual circumstances must be taken into account. Your doctor can determine whether you would need additional monitoring.

For most people with mild liver enzyme elevations or early fatty liver disease, semaglutide may actually be beneficial rather than harmful. But those with advanced liver disease or active liver inflammation may need specialized evaluation before starting treatment.

Discuss your concerns with your doctor to ensure that you understand the nature of the therapy. If there are unexpected changes, contact your doctor immediately to address the issues promptly.

Your healthcare provider may recommend baseline liver function tests before starting semaglutide, especially if you have risk factors for liver disease. This creates a baseline for monitoring any changes during treatment.

 

Quick Summary Box

• Clinical trials show semaglutide does not cause liver damage in the vast majority of users

• Studies demonstrate reduced liver fat content and improved liver enzyme levels

• Semaglutide can reduce liver fat by 30-40% in NAFLD patients within 24 weeks

• The 10-15% weight loss typically achieved supports liver health improvements

• Routine liver function monitoring is not required for most patients

• Isolated reports of liver problems are extremely uncommon and often involve multiple risk factors

Related Resources

Kratom and Your Liver: Unpacking the Hidden Risks

What Causes Hypodensity in Liver? Comprehensive Guide

How Serious is a Nodule on the Liver? What You Need to Know

Frequently Asked Questions

Can semaglutide treat fatty liver disease?

Yes, semaglutide can treat fatty liver disease. The medication is primarily used to treat diabetes but in so doing it has indirectly benefited the liver through its weight loss effects.

What are the side effects of semaglutide?

Common side effects include nausea, vomiting, and digestive issues. Most side effects are gastrointestinal and tend to improve over time as your body adapts to the medication.

Is semaglutide safe for people with liver disease?

People with mild liver conditions often benefit from semaglutide. But if you have advanced liver disease, you should discuss treatment carefully with your healthcare provider. Individual assessment is important for safety.

 

Written by Jaclyn P. Leyson-Azuela, RMT, MD, MPH
Jaclyn P. Leyson-Azuela, RMT, MD, MPH, is a licensed General Practitioner and Public Health Expert. She currently serves as a physician in private practice, combining clinical care with her passion for preventive health and community wellness.

 

References

Bandyopadhyay, S., Das, S., Samajdar, S. S., & Joshi, S. R. (2023). Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 17(10), 102849. https://doi.org/10.1016/j.dsx.2023.102849 

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2022). Semaglutide for the treatment of overweight and obesity: A review. Diabetes, Obesity and Metabolism, 25(1). https://doi.org/10.1111/dom.14863 

Boron, K., & Narang, D. (2025). Elevated liver enzymes in a patient with obesity and sleep-related eating disorder during semaglutide therapy. Endocrine Abstracts. https://doi.org/10.1530/endoabs.110.ep1006 

Brunner, K. T., Henneberg, C. J., Wilechansky, R. M., & Long, M. T. (2019). Nonalcoholic Fatty Liver Disease and Obesity Treatment. Current Obesity Reports, 8(3), 220–228. https://doi.org/10.1007/s13679-019-00345-1 

Dutta, D., Kumar, M., K.S. Shivaprasad, Kumar, A., & Sharma, M. (2022). Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research and Reviews, 16(6), 102539–102539. https://doi.org/10.1016/j.dsx.2022.102539 

Galeano, S. F., & Karthik Gnanapandithan. (2023). S3653 Semaglutide-Induced Hepatotoxicity: A Rare Case of Drug Induced Liver Injury. The American Journal of Gastroenterology, 118(10S), S2370–S2370. https://doi.org/10.14309/01.ajg.0000964252.91007.e2 

Hsu, C. C., Ness, E., & Kowdley, K. V. (2017). Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Advances in Nutrition, 8(2), 253–265. https://doi.org/10.3945/an.116.013730 

Klein, H. E. (2025, May 12). Semaglutide May Reduce Liver Fibrosis in Patients With MASH. AJMC. https://www.ajmc.com/view/semaglutide-may-reduce-liver-fibrosis-in-patients-with-mash 

Kommu, S., & Whitfield, P. (2024, February 11). Semaglutide. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK603723 /

Newsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019). Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacology & Therapeutics, 50(2), 193–203. https://doi.org/10.1111/apt.15316 

Nonalcoholic Fatty Liver Disease (NAFLD). (2025, February 13). American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld/ 

Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2413258 

Semaglutide reduces severity of common liver disease in people with HIV. (2024, March 5). National Institutes of Health (NIH). https://www.nih.gov/news-events/news-releases/semaglutide-reduces-severity-common-liver-disease-people-hiv 

Verma, S., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Jensen, C., Kandler, K., Kushner, R. F., Rubino, D. M., & Kosiborod, M. N. (2023). Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine, 55, 101737. https://doi.org/10.1016/j.eclinm.2022.101737 

Wilding, J. P. H., Batterham, R. L., & Calanna, S. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. PubMed. https://doi.org/10.1056/NEJMoa2032183